Horizon Europe is the European Union (EU) funding programme for the period 2021 – 2027, which targets the sectors of research and innovation. The programme’s budget is around € 95.5 billion, of which € 5.4 billion is from NextGenerationEU to stimulate recovery and strengthen the EU’s resilience in the future, and € 4.5 billion is additional aid.
This topic will contribute to the achievement of the Mission’s objective to better understand cancer by studying tumour-host interactions underpinning the development and progression of cancer, including in advanced localised or metastatic disease. The focus should be on poorly-understood cancers and their subtypes in children, adolescents, adults and the elderly.
Proposals should address all of the following:
Challenges include uncovering which patients benefit from interventions or risk potentially debilitating side-effects, as well as ensuring affordability of interventions across Europe, across all age groups. This requires a new dimension and level of investment in innovative research with a view to intercept disease. It also requires investing in high-risk, high-reward research projects to deliver a proof-of-concept of potentially disruptive new approaches. These approaches include monitoring treatment and disease progression and disclosing disease pathways, such as through single-cell -omics technologies, innovative disease models, advanced imaging technologies, or artificial intelligence and machine learning.
100%
EU Contribution per project: between €7,00 and €12,00 million
Research and Innovation Foundation
29a Andrea Michalakopoulou, 1075 Nicosia
P.B. 23422, 1683 Nicosia
Telephone: +357 22205000
Fax: +357 22205001
Email: support@research.org.cy
Contact Person:
George Christou
Scientific Officer
gchristou@research.org.cy
(Publish Date: 07/02/2023-for internal use only)